[1]靖 洁.美沙拉嗪联合双歧杆菌三联活菌治疗溃疡性结肠炎的疗效[J].医学信息,2021,34(13):163-165.[doi:10.3969/j.issn.1006-1959.2021.13.045]
　JING Jie.Efficacy of Mesalazine Combined with Live Bifidobacterium Triple Viable Bacteria in the Treatment of Ulcerative Colitis[J].Medical Information,2021,34(13):163-165.[doi:10.3969/j.issn.1006-1959.2021.13.045]
点击复制

美沙拉嗪联合双歧杆菌三联活菌治疗溃疡性结肠炎的疗效()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年13期
页码:
163-165
栏目:
药物与临床
出版日期:
2021-07-01

文章信息/Info

Title:
Efficacy of Mesalazine Combined with Live Bifidobacterium Triple Viable Bacteria in the Treatment of Ulcerative Colitis
文章编号:
1006-1959（2021）13-0163-03
作者:
靖 洁
（佳木斯中心医院消化内科，黑龙江 佳木斯 154002）
Author(s):
JING Jie
(Department of Gastroenterology,Jiamusi Central Hospital,Jiamusi 154002,Heilongjiang,China)
关键词:
美沙拉嗪; 双歧杆菌三联活菌; 溃疡性结肠炎; 炎性因子
Keywords:
Mesalazine; Bifidobacterium triple viable bacteria; Ulcerative colitis; Inflammatory factors
分类号:
R574.62
DOI:
10.3969/j.issn.1006-1959.2021.13.045
文献标志码:
A
摘要:
目的 分析美沙拉嗪与双歧杆菌三联活菌联合治疗溃疡性结肠炎的疗效及对IL-1β、IL-8、TNF-α影响。方法 选取2017年5月~2020年7月因溃疡性结肠炎于佳木斯中心医院治疗的80例患者作为研究对象，采用随机数字表法分为观察组与对照组，每组40例。对照组予以美沙拉嗪治疗，观察组给予美沙拉嗪联合双歧杆菌三联活菌治疗。比较两组临床疗效、症状评分、炎性因子水平[白介素-1β（IL-1β）、白介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）]以及不良反应发生情况。结果 观察组临床治疗总有效率高于对照组（P＜0.05）；两组治疗后腹泻、脓血便和腹痛症状评分均低于治疗前，且观察组低于对照组（P＜0.05）；两组治疗后IL-1β、IL-6、TNF-α低于治疗前，且观察组低于对照组（P＜0.05）；两组不良反应发生率比较，差异无统计学意义（P＞0.05）。结论 美沙拉嗪与双歧杆菌三联活菌联合治疗溃疡性结肠炎的疗效确切，在改善患者临床症状的同时缓解了机体炎症反应，且联合用药安全性较高。
Abstract:
Objective To analyze the efficacy of mesalazine and bifidobacterium triple viable bacteria in the treatment of ulcerative colitis and its influence on IL-1β, IL-8 and TNF-α.Methods A total of 80 patients who were treated in Jiamusi Central Hospital for ulcerative colitis from May 2017 to July 2020 were selected as the research objects. They were divided into observation group and control group by random number table method, with 40 cases in each group.The control group was treated with mesalazine, and the observation group was treated with mesalamine combined with live bifidobacteria. The clinical efficacy, symptom scores, levels of inflammatory factors [interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α)] and the occurrence of adverse reactions were compared between the two groups.Results The total effective rate of clinical treatment in the observation group was higher than that in the control group (P＜0.05);The scores of diarrhea, pus and blood in the stool and abdominal pain symptoms after treatment in the two groups were lower than those before treatment, and the observation group was lower than the control group (P＜0.05);IL-1β, IL-6 and TNF-α after treatment in the two groups were lower than before treatment, and the observation group was lower than the control group (P＜0.05);There was no statistically significant difference in the incidence of adverse reactions between the two groups (P＞0.05).Conclusion The combination of mesalazine and bifidobacterium viable triple bacteria is effective in treating ulcerative colitis. It can improve the clinical symptoms of patients and relieve the body’s inflammatory response, and the combination of drugs is safer.

参考文献/References:

[1]蒋圣君,毛伯能.美沙拉嗪、双歧杆菌三联活菌联合复方谷氨酰胺治疗活动期轻中度溃疡性结肠炎的研究[J].河北医药,2018,40(23):21-25. [2]余海平,李春耕.双歧杆菌三联活菌片联合美沙拉嗪对溃疡性结肠炎患者免疫功能及肠黏膜屏障功能的影响[J].现代中西医结合杂志,2018,27(29):3220-3223. [3]胡莲,廉华,周涛.双歧杆菌三联活菌胶囊联合美沙拉嗪对溃疡性结肠炎患者血清中炎症因子及环氧酶-2含量的影响[J].实用医院临床杂志,2018,15(1):76-79. [4]Mosli M,Alfaer S,Almalaki T,et al.Baseline risk assessment of patients with ulcerative colitis:does initial treatment selection influence outcomes[J].European Journal of Gastroenterology&Hepatology,2019,31(1):80-85. [5]刘伟.美沙拉嗪联合双歧三联活菌治疗溃疡性结肠炎疗效及对肿瘤坏死因子、白细胞介素-6、白细胞介素-8水平影响[J].临床军医杂志,2018,46(8):987-988,990. [6]中华中医药学会.溃疡性结肠炎诊疗指南[J].中国中医药现代远程教育,2011,9(10):126-128. [7]张晓慧.单用美沙拉嗪及联用双歧三联活菌治疗溃疡性结肠炎的疗效及对肿瘤坏死因子-α、白介素-6及白介素-8的影响分析[J].实用临床医药杂志,2018,12(3):112-114. [8]冯显清,梁川,刘然,等.双歧杆菌三联活菌胶囊联合美沙拉嗪对溃疡性结肠炎患者免疫功能及肠黏膜屏障功能的影响[J].国际消化病杂志,2018,38(2):69-72. [9]翁艳.枯草杆菌二联活菌肠溶胶囊联合美沙拉嗪对溃疡性结肠炎患者的疗效及血清SODMDATNF-α的影响[J].河北医学,2018,24(12):1945-1948. [10]Li HB,Chen MY,Qiu ZW,et al.Efficacy and safety of Kangfuxin liquid combined with aminosalicylic acid for the treatment of ulcerative colitis:A systematic review and meta-analysis[J].Medicine,2018,97(21):10807-10810. [11]Choi CH,Park SJ,Im JP,et al.P477 The efficacy of adalimumab for the treatment of Korean patients with ulcerative colitis and predictors of response: Preliminary results[J].Journal of Crohns and Colitis,2018,25(1):S345-S346. [12]张漫,唐庆,刘星星,等.百令胶囊联合美沙拉嗪治疗溃疡性结肠炎疗效及对患者血清白细胞介素35的影响[J].中国药师,2018,21(12):75-76,109. [13]韩丹,恽海峰,金逸纯,等.平溃灌肠剂对溃疡性结肠炎肠双歧杆菌黏附性及相关炎性细胞因子的影响[J].国际中医中药杂志,2019,41(9):969-975. [14]张莉,顾清,代小松,等.美沙拉嗪联合布拉氏酵母菌散治疗溃疡性结肠炎的疗效及对炎症因子的影响[J].西部医学,2018,30(7):1002-1004,1009.

相似文献/References:

[1]徐 杰.美沙拉嗪与柳氮磺吡啶治疗溃疡性结肠炎的效果比较[J].医学信息,2020,33(04):151.[doi:10.3969/j.issn.1006-1959.2020.04.049]
　XU Jie.Comparison of Mesalazine and Sulfasalazine in Treating Ulcerative Colitis[J].Medical Information,2020,33(13):151.[doi:10.3969/j.issn.1006-1959.2020.04.049]
[2]钟 烨,余 勇.葛根芩连汤联合美沙拉嗪治疗溃疡性结肠炎的疗效及对患者炎性因子的影响[J].医学信息,2023,36(16):141.[doi:10.3969/j.issn.1006-1959.2023.16.028]
　ZHONG Ye,YU Yong.Efficacy of Gegen Qinlian Decoction Combined with Mesalazine in the Treatment of Ulcerative Colitis and its Effect on Inflammatory Factors[J].Medical Information,2023,36(13):141.[doi:10.3969/j.issn.1006-1959.2023.16.028]

更新日期/Last Update: 1900-01-01